122 related articles for article (PubMed ID: 35249267)
1. Risk factors associated with the onset of lomustine-induced neutropenia in tumour-bearing dogs.
Treggiari E; Cossu G; Valenti P; Taylor A
Vet Comp Oncol; 2022 Sep; 20(3):577-586. PubMed ID: 35249267
[TBL] [Abstract][Full Text] [Related]
2. CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).
Heading KL; Brockley LK; Bennett PF
Aust Vet J; 2011 Apr; 89(4):109-16. PubMed ID: 21418164
[TBL] [Abstract][Full Text] [Related]
3. Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer.
Burton JH; Stanley SD; Knych HK; Rodriguez CO; Skorupski KA; Rebhun RB
J Vet Intern Med; 2016; 30(1):242-6. PubMed ID: 26682700
[TBL] [Abstract][Full Text] [Related]
4. Treatment of canine mast cell tumors with CCNU (lomustine).
Rassnick KM; Moore AS; Williams LE; London CA; Kintzer PP; Engler SJ; Cotter SM
J Vet Intern Med; 1999; 13(6):601-5. PubMed ID: 10587263
[TBL] [Abstract][Full Text] [Related]
5. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs.
Moore AS; London CA; Wood CA; Williams LE; Cotter SM; L'Heureux DA; Frimberger AE
J Vet Intern Med; 1999; 13(5):395-8. PubMed ID: 10499719
[TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity associated with CCNU (lomustine) chemotherapy in dogs.
Kristal O; Rassnick KM; Gliatto JM; Northrup NC; Chretin JD; Morrison-Collister K; Cotter SM; Moore AS
J Vet Intern Med; 2004; 18(1):75-80. PubMed ID: 14765735
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma.
Rassnick KM; Bailey DB; Malone EK; Flory AB; Kiselow MA; Intile JL
J Am Anim Hosp Assoc; 2014; 50(3):167-73. PubMed ID: 24659727
[TBL] [Abstract][Full Text] [Related]
8. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
[TBL] [Abstract][Full Text] [Related]
9. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma.
Rassnick KM; Moore AS; Russell DS; Northrup NC; Kristal O; Bailey DB; Flory AB; Kiselow MA; Intile JL
J Vet Intern Med; 2010; 24(6):1528-31. PubMed ID: 21155191
[TBL] [Abstract][Full Text] [Related]
10. CCNU in the treatment of canine epitheliotropic lymphoma.
Williams LE; Rassnick KM; Power HT; Lana SE; Morrison-Collister KE; Hansen K; Johnson JL
J Vet Intern Med; 2006; 20(1):136-43. PubMed ID: 16496933
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dexamethasone as a chemoprotectant for CCNU-induced bone marrow suppression in dogs.
Intile JL; Rassnick KM; Bailey DB; Al-Sarraf R; Chretin JD; Balkman CE; Flory AB; Kiselow MA; Wakshlag JJ
Vet Comp Oncol; 2009 Mar; 7(1):69-77. PubMed ID: 19222832
[TBL] [Abstract][Full Text] [Related]
12. Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): a retrospective study of 46 cases (1999-2004).
Risbon RE; de Lorimier LP; Skorupski K; Burgess KE; Bergman PJ; Carreras J; Hahn K; Leblanc A; Turek M; Impellizeri J; Fred R; Wojcieszyn JW; Drobatz K; Clifford CA
J Vet Intern Med; 2006; 20(6):1389-97. PubMed ID: 17186855
[TBL] [Abstract][Full Text] [Related]
13. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs.
Flory AB; Rassnick KM; Al-Sarraf R; Bailey DB; Balkman CE; Kiselow MA; Autio K
J Vet Intern Med; 2008; 22(1):164-71. PubMed ID: 18289305
[TBL] [Abstract][Full Text] [Related]
14. Lomustine chemotherapy for the treatment of presumptive haemophagocytic histiocytic sarcoma in Flat-coated Retrievers.
Elliott J
Aust Vet J; 2018 Dec; 96(12):502-507. PubMed ID: 30478839
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant CCNU (lomustine) and prednisone chemotherapy for dogs with incompletely excised grade 2 mast cell tumors.
Hosoya K; Kisseberth WC; Alvarez FJ; Lara-Garcia A; Beamer G; Stromberg PC; Couto CG
J Am Anim Hosp Assoc; 2009; 45(1):14-8. PubMed ID: 19122059
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of dacarbazine as a rescue agent for histiocytic sarcoma in dogs.
Kezer KA; Barber LG; Jennings SH
Vet Comp Oncol; 2018 Mar; 16(1):77-80. PubMed ID: 28419676
[TBL] [Abstract][Full Text] [Related]
17. The use of lithium carbonate to prevent lomustine-induced myelosuppression in dogs: a pilot study.
Abrams-Ogg AC
Can J Vet Res; 2011 Jan; 75(1):73-6. PubMed ID: 21461200
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of metronomic administration of lomustine in dogs with cancer.
Tripp CD; Fidel J; Anderson CL; Patrick M; Pratt C; Sellon R; Bryan JN
J Vet Intern Med; 2011; 25(2):278-84. PubMed ID: 21314727
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma.
Cannon C; Borgatti A; Henson M; Husbands B
J Small Anim Pract; 2015 Jul; 56(7):425-9. PubMed ID: 25828786
[TBL] [Abstract][Full Text] [Related]
20. Low apparent risk of CCNU (lomustine)-associated clinical hepatotoxicity in cats.
Musser ML; Quinn HT; Chretin JD
J Feline Med Surg; 2012 Dec; 14(12):871-5. PubMed ID: 22772480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
